The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–935 of 935
Kim, S., Clark, J. I., & Small, W. C. (2026) · Advances in Radiation Oncology · doi:10.1016/j.adro.2026.102214
Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide–HLA complex
Watkins-Yoon, J., Lu, W.-C., Petrunak, E. M., Tubo, N. J., Halmos, S., McConaughy, W., Ciuffa, R., Weber, C. R., Friedensohn, S., Justesen, S. F. L., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2731282
Bao, Q.-H., Wu, A., Pang, J.-M., Wang, J.-W., Chen, Q., & Wu, S.-W. (2026) · Oncology Reviews · doi:10.3389/or.2026.1905358
Pires, L., Calçada, C., Cerqueira-Rodrigues, B., Fan, Y., George, J. T., McGaha, T. L., & Wilson, B. C. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03585-w
Aktuelle Behandlung des Melanoms
Gutzmer, R., Angela, Y., Müller-Richter, U., & Alter, M. (2026) · Die MKG-Chirurgie · doi:10.1007/s12285-026-00589-6
Proteogenomic Analysis of HDAC4 and HDAC5 in Uveal Melanoma
Mergener, S., Kutzner, T. J., Schneider, M., González-Gimeno, T., Zheng, Y., Berchner‐Pfannschmidt, U., Helm, D., Giebel, B., Bechrakis, N. E., & Peña‐Llopis, S. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01652-9
Koumprentziotis, I., Bakella, A., Nikolaou, V. A., & Koumaki, D. (2026) · Cancers · doi:10.3390/cancers18193071
Fückel, S., Dix, C., Hepp, T., Mathy, C. S., Tkotz, K., Uder, M., Berking, C., Erdmann, M., & Bäuerle, T. (2026) · Livers · doi:10.3390/livers6050100
Zhang, J., An, H., 于传飞, Li, W., Li, M., & Wang, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198859
Rifaldi, F., de Braud, F., Vecchio, M. D., & Guardo, L. D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1934256
Niazi, S. K., Magoola, M., & Mariam, Z. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00084-z
T cell receptor-engineered T cells for hepatocellular carcinoma: next steps and future perspectives
Li, Z., Shu, J., Zhang, Q., Su, S., Zhou, J., Luan, Y., Xu, J., Gu, J., & Huang, X. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00075-1
Taglialatela, I., Corcia, L. D., Boutros, A., Gatti, A., Sponghini, A. P., Esposto, E., Farinelli, P., Giorgione, R., Zottarelli, F., Zavattaro, E., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101482
Turning cold tumors hot: Strategies to enhance antitumor immunity
Steffensen, V. G., Bratina, M., Tsiavou, C., Schmiegelow, K., & Zio, D. D. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20260378
The tumor targetome in CAR-T and TCR-T cell therapy
Wang, S., Sun, B., Rai, S., Yang, X., Banday, S., Memon, A., Kearl, T., Hematti, P., Shah, N., Dong, J., et al. (2026) · Targetome · doi:10.48130/targetome-0026-0050
Qi, H., Zhang, H., Wang, C., Song, S., Du, Y., Yu, L., Shao, J., Qian, X., Cao, Y., Liu, B., et al. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.116266
Wu, Y., & Fan, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105654
Immune Cell Engagers and “Masking Immunotherapy” for Solid Tumors: Focus on Head and Neck Cancers
Nardo, G., Lenoci, D., Lucchetta, M., Licitra, L. F., Cecco, L. D., & Cavalieri, S. (2026) · Cancers · doi:10.3390/cancers18203401
Huang, P., Wu, W., Min, Y., Zhang, Y., Tao, Y., Liu, Z., Wei, Z., & Peng, X. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00848-3
Bispecific T-cell engagers beyond hematology: Expanding uses in solid tumors
Rychalsky, K., Luon, D., & Tracchia, J. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261500125
Uveal melanoma: innovations in therapy, prognosis, and imaging
Rao, N., Nagarajan, S., & Dalvin, L. A. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2755251
The mask of sanity: Cancer and autoimmunity as complementary failures of semiotic classification
Bukkuri, A. (2026) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2026109
Bispecific immune cell engagers for solid tumors: Molecular engineering and therapeutic perspectives
Kumari, P., Srivastava, A., Raul, S. S., Priyanjali, B., Dey, A., & Bordoloi, D. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105676
McKean, M. A., Chmielowski, B., Butler, M. O., Carvajal, R. D., Rodon, J. A., Carlino, M. S., Kim, K. B., Wise-Draper, T. M., Khan, S. A., Salama, A. K. S., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00802
Self-citationAntigen-Guided Synthetic Receptor Engineering for Safer T Cell Immunotherapy in Solid Tumors
Kang, S., Cho, H. J., Kim, J.-H., & Lee, H. (2026) · Immune Network · doi:10.4110/in.2026.26.e40
Malissen, N., Monestier, S., & Gaudy-Marqueste, C. (2026) · EMC - Dermatologie · doi:10.1016/s0246-0319(26)43951-5
In vivo spleen-oriented mRNA translation (SPOT) of T cell engager potentiates cancer immunotherapy
Shi, T., Zhong, L., Deng, C., Ren, Q., Chang, L., Zhang, S., Wu, J., Zheng, Y., Piao, X., Ren, K., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.031
Dana, I. G. N. A. W. K., Yuliawati, P., Utari, N. M. L., & Adnyana, I. W. L. (2026) · Open Access Indonesian Journal of Medical Reviews · doi:10.37275/oaijmr.v6i6.1000
Arnold, L., Ertl, C., Rejeski, K., David-Rus, R., Kong-Bild, M., Pusl, R., Frölich, L., Tomsitz, D., von Baumgarten, L., Subklewe, M., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117817
T-cell engagers in solid tumors: challenges and emerging strategies
Forero, J., Jani, R. T., Zheng, X., Jani, C., & Bilušić, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1956728
Junker, F., Darwish, M., Yadav, M., Habigt, C., Bergauer, T., Dejardin, D., Duarte, J. M., Muñoz‐Couselo, E., Bechter, O. E., Teichgräber, V., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015065
Alhadlag, A. S. (2026) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2026.2757565
Biomarkers for Cancer Immunotherapy: Advances, Challenges, and Clinical Applications
Abbasi, A. A., & Haq, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219882
Using liver-directed therapies as backbone for combination-treatments in metastatic uveal melanoma
Wong, A., Kapiteijn, E., Piperno-Neumann, S., & Bagge, R. O. (2026) · ESMO rare cancers. · doi:10.1016/j.esmorc.2026.100548
Self-citation
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
